A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBA
What they do
Healx utilizes its AI platform, HealNet, to analyze extensive biomedical data and identify novel drug combinations and repositioning opportunities for rare diseases. The system serves patient groups, academic institutions, and biopharma partners looking to accelerate therapies into clinical trials.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Rare disease therapies
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- Cambridge, UK
- Region
- Europe
- Founded
- 2014
- Total funding
- $103M raised
Notable investors: Atomico, Intel Capital, Balderton Capital, Global Brain.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Beyond the Genetic Ceiling: How Scholar Rock's FDA Approval for Isembyld Unlocks the Muscle-Directed Neuromuscular Economy
Dr. Dereck Mush, MD, MBA
The ALK2 Opening: What Atebrioz Means for Rare Bone Disease
Dr. Dereck Mush, MD, MBA
The Oral Transition in Rare Disease Crisis Management: Deucrictibant, Bradykinin B2 Receptors, and the Next Phase of Acute HAE Care
Dr. Dereck Mush, MD, MBA